Showing results (71-80 of 171) with videos related to

Sort By:
Pageof 18
Clinical Lung Cancer|February 21, 2023
Upfront and Repeated Stereotactic Radiosurgery in Patients With Brain Metastases From NSCLCAnna S Krämer, Sebastian Adeberg, Dorothea Kronsteiner, et al.
BMC Pulmonary Medicine|June 27, 2022
Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysisMiriam Blasi, Martin E Eichhorn, Petros Christopoulos, et al.
Nature Reviews. Clinical Oncology|August 27, 2024
Tumour mutational burden: clinical utility, challenges and emerging improvementsJan Budczies, Daniel Kazdal, Michael Menzel, et al.
Translational Lung Cancer Research|August 25, 2021
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
NPJ Precision Oncology|December 8, 2021
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysisArlou Kristina Angeles, Petros Christopoulos, Zhao Yuan, et al.
Cancer Management and Research|December 18, 2018
Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapyDenise Bernhardt, Sophie Aufderstrasse, Laila König, et al.
Histopathology|July 8, 2020
Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancerKatharina Kriegsmann, Christiane Zgorzelski, Thomas Muley, et al.
Translational Lung Cancer Research|June 10, 2024
A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring <i>EML4-ALK</i> rearrangementWenbin Hu, Jiaming Zhao, Guoxia Wang, et al.
JTO Clinical and Research Reports|July 26, 2022
<b>Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Sta</b> <b>ge NSCLC With High Programmed Death-Ligand 1 Express</b> <b>ion</b>Timothy Rajakumar, Rastislav Horos, Paul Kittner, et al.
Translational Lung Cancer Research|December 13, 2023
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel <i>LRRTM4-ALK</i> fusion: a case reportBowen Li, Ziqi Jia, Zhicheng Huang, et al.
Pageof 18